New drug AZD9829 targets hard-to-treat blood cancers in early trial
NCT ID NCT06179511
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tests a new drug, AZD9829, in people with blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD123 found on cancer cells. The main goals are to find a safe dose and check for side effects. About 56 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Chapel Hill, North Carolina, 27514, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Milwaukee, Wisconsin, 53226, United States
-
Research Site
Heidelberg, 3084, Australia
-
Research Site
Melbourne, VIC 3000, Australia
-
Research Site
Tianjin, 300020, China
-
Research Site
Frankfurt, 60590, Germany
-
Research Site
Bologna, 40138, Italy
-
Research Site
Kashiwa, 227-8577, Japan
-
Research Site
Osaka, 545-8586, Japan
-
Research Site
Yoshida-gun, 910-1193, Japan
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Barcelona, 08035, Spain
-
Research Site
Salamanca, 37007, Spain
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Manchester, M204BX, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test outsmart deadly fungal infections in blood cancer?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Can a lower drug dose make stem cell transplants safer?
- Plant pigment could soothe Radiation's harsh side effect in blood cancer treatment
- New Antibody-Drug conjugate targets Hard-to-Treat cancers